E

Exelixis
D

EXEL

33.690
USD
-0.97
(-2.80%)
مغلق
حجم التداول
109,415
الربح لكل سهم
1
العائد الربحي
-
P/E
22
حجم السوق
9,621,157,184
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABBV
    ABBV
    -2.390
    (-1.36%)
    173.030 USD
    A
    ARRY
    -0.10500
    (-1.92%)
    5.37500 USD
    BMY
    BMY
    -0.830
    (-1.44%)
    56.830 USD
    GILD
    GILD
    -2.130
    (-2.30%)
    90.630 USD
    I
    INCY
    -1.820
    (-2.62%)
    67.550 USD
    S
    SGEN
    0
    (0%)
    0.000000 USD
    المزيد
الأخبار

العنوان: Exelixis

القطاع: Healthcare
الصناعة: Biotechnology
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.